Related Experiment Video
Updated: Jul 30, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
[Pharmacological trials evaluating treatment options for neuropsychiatric symptoms in post-COVID. A narrative review]
Noémie Lejay1, Paolo Salvioni Chiabotti1, Aurélie Ducrot2
1Centre Leenaards de la mémoire, Département des neurosciences cliniques, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne.
Abstract:
Post-COVID prevalence's is estimated at 10 % in the general population. The neuropsychiatric symptoms, which are frequent (up to 30 %), can severely affect the quality of life of patients affected by this condition, notably by significantly reducing their working ability. To date, no pharmacologic treatment is available for post-COVID, apart from symptomatic treatments. A large number of pharmacological clinical trials for post-COVID are underway since 2021. A number of these trials targets neuropsychiatric symptoms, based on the various underlying pathophysiological hypotheses. The objective of this narrative review is to provide an overview of these ongoing trials targeting neuropsychiatric symptoms in post-COVID.
More Related Videos
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
09:29Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications
Psychosis and Antipsychotic Drugs: Overview
Clinical Trials: Overview
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview